サマリー

着床前遺伝子診断（PGD）の世界市場規模は、2020年に8152万ドル、2021年から2030年までCAGR10.3%を記録し、2030年には2億1718万ドルに達すると予測されています。着床前遺伝子診断（PGD）は、胚のスクリーニングと呼ばれています。体外受精（IVF）による胚の遺伝子検査を含む遺伝学の一分野である。
PGDは、脊髄性筋萎縮症や嚢胞性線維症などの重篤な遺伝性疾患、染色体疾患、遺伝性疾患を移しやすいカップルの選択的妊娠中止のリスクを排除するものである。
PGDは、遺伝子、遺伝性、染色体異常のない健康な胚のための効果的な解決策を提供します。これは現代の遺伝学研究において進化した技術です。また、3倍体、サラセミア、デュシェンヌ型筋ジストロフィー（DMD）など、遺伝性、染色体、遺伝性疾患の有病率は年々増加しており、変異の診断のためにPGDが必要とされています。また、ヒト白血球抗原（HLA）プロファイルを選択し、疾患を持つ兄弟姉妹をマッチングさせたり、家族内の性別のバランスを取るためにPGD技術の利用が増加し、PGD市場の成長に拍車をかけています。さらに、不妊率の上昇とPGD技術に関する認知度の向上が市場の成長を後押ししています。
PGDの世界市場は、検査の種類と地域によって区分されます。検査タイプ別では、染色体異常、異数性、X連鎖性疾患、単一遺伝子障害、HLAタイピング、性別選択、その他に分類されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されます。
世界市場で事業を展開する主要企業は、市場への働きかけを強化し、市場での厳しい競争を維持するために、製品発売などの主要戦略を採用しています。
競合分析
本レポートで紹介する主な市場参加者は、Agilent Technologies, Inc.、CeGaT GmbH、Illumina Inc.、Invitae Corporation、Laboratory Corporation of America Holdings、Natera Inc、PacGenomics、PerkinElmer, Inc、Quest Diagnostics Inc、Reproductive Genetic Innovations (RGI) などです。
ステークホルダーにとっての主なメリット
本レポートは、現在および新興のPGD市場の動向とダイナミクスについて広範な分析を提供しています。
2020年から2030年までの主要な市場セグメントの市場推定を構築することで、詳細な市場分析を行っています。
PGD市場の広範な分析は、主要製品のポジショニングと市場フレームワーク内の上位競合企業のモニタリングを行うことによって実施されます。
全地域の包括的な分析は、優勢な機会を決定するために提供されます。
2021年から2030年までの世界のPGD市場の予測分析が含まれています。
PGD市場内の主要な市場プレイヤーを本レポートでプロファイリングし、その戦略を徹底的に分析することで、PGD業界の競争展望を理解するのに役立ちます。

ページTOPに戻る

目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Chromosomal Abnormalities
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Aneuploidy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 X-linked diseases
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Single Gene Disorders
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 HLA Typing
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Gender selection
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Others
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
CHAPTER 5: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 Asia-Pacific
5.2.1 Key trends and opportunities
5.2.2 Asia-Pacific Market size and forecast, by Test Type
5.2.3 Asia-Pacific Market size and forecast, by country
5.2.3.1 China
5.2.3.1.1 Market size and forecast, by Test Type
5.2.3.2 Japan
5.2.3.2.1 Market size and forecast, by Test Type
5.2.3.3 India
5.2.3.3.1 Market size and forecast, by Test Type
5.2.3.4 South Korea
5.2.3.4.1 Market size and forecast, by Test Type
5.2.3.5 Rest Of Asia Pacific
5.2.3.5.1 Market size and forecast, by Test Type
5.3 LAMEA
5.3.1 Key trends and opportunities
5.3.2 LAMEA Market size and forecast, by Test Type
5.3.3 LAMEA Market size and forecast, by country
5.3.3.1 Latin America
5.3.3.1.1 Market size and forecast, by Test Type
5.3.3.2 Middle East
5.3.3.2.1 Market size and forecast, by Test Type
5.3.3.3 Africa
5.3.3.3.1 Market size and forecast, by Test Type
5.4 North America
5.4.1 Key trends and opportunities
5.4.2 North America Market size and forecast, by Test Type
5.4.3 North America Market size and forecast, by country
5.4.3.1 U.S.
5.4.3.1.1 Market size and forecast, by Test Type
5.4.3.2 Canada
5.4.3.2.1 Market size and forecast, by Test Type
5.4.3.3 Mexico
5.4.3.3.1 Market size and forecast, by Test Type
5.5 Europe
5.5.1 Key trends and opportunities
5.5.2 Europe Market size and forecast, by Test Type
5.5.3 Europe Market size and forecast, by country
5.5.3.1 Germany
5.5.3.1.1 Market size and forecast, by Test Type
5.5.3.2 France
5.5.3.2.1 Market size and forecast, by Test Type
5.5.3.3 U.K.
5.5.3.3.1 Market size and forecast, by Test Type
5.5.3.4 Italy
5.5.3.4.1 Market size and forecast, by Test Type
5.5.3.5 Rest of Europe
5.5.3.5.1 Market size and forecast, by Test Type
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 Agilent Technologies, Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 cegat gmbh
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 Illumina Inc.
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 Invitae Corporation
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 Laboratory Corporation of America Holdings
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 Natera Inc.
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 pacgenomics
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 PerkinElmer, Inc.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 Quest Diagnostics Inc.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 Reproductive Genetic Innovations (RGI)
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 2. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR CHROMOSOMAL ABNORMALITIES, BY REGION , 2020-2030,($THOUSAND)
TABLE 3. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET CHROMOSOMAL ABNORMALITIES BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 4. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR ANEUPLOIDY, BY REGION , 2020-2030,($THOUSAND)
TABLE 5. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET ANEUPLOIDY BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 6. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR X-LINKED DISEASES, BY REGION , 2020-2030,($THOUSAND)
TABLE 7. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET X-LINKED DISEASES BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 8. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR SINGLE GENE DISORDERS, BY REGION , 2020-2030,($THOUSAND)
TABLE 9. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SINGLE GENE DISORDERS BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 10. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR HLA TYPING, BY REGION , 2020-2030,($THOUSAND)
TABLE 11. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET HLA TYPING BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 12. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR GENDER SELECTION, BY REGION , 2020-2030,($THOUSAND)
TABLE 13. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET GENDER SELECTION BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 14. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($THOUSAND)
TABLE 15. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OTHERS BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 16. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION, 2020-2030,($THOUSAND)
TABLE 17. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 18. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 19. CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 20. JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 21. INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 22. SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 23. REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 24. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 25. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 26. LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 27. MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 28. AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 29. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 30. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 31. U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 32. CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 33. MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 34. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 35. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 36. GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 37. FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 38. U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 39. ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 40. REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 41.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 42.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 43.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 44.AGILENT TECHNOLOGIES, INC.: NET SALES,
TABLE 45.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 46.CEGAT GMBH: COMPANY SNAPSHOT
TABLE 47.CEGAT GMBH: OPERATING SEGMENTS
TABLE 48.CEGAT GMBH: PRODUCT PORTFOLIO
TABLE 49.CEGAT GMBH: NET SALES,
TABLE 50.CEGAT GMBH: KEY STRATERGIES
TABLE 51.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 52.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 53.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 54.ILLUMINA INC.: NET SALES,
TABLE 55.ILLUMINA INC.: KEY STRATERGIES
TABLE 56.INVITAE CORPORATION: COMPANY SNAPSHOT
TABLE 57.INVITAE CORPORATION: OPERATING SEGMENTS
TABLE 58.INVITAE CORPORATION: PRODUCT PORTFOLIO
TABLE 59.INVITAE CORPORATION: NET SALES,
TABLE 60.INVITAE CORPORATION: KEY STRATERGIES
TABLE 61.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 62.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
TABLE 63.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 64.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,
TABLE 65.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
TABLE 66.NATERA INC.: COMPANY SNAPSHOT
TABLE 67.NATERA INC.: OPERATING SEGMENTS
TABLE 68.NATERA INC.: PRODUCT PORTFOLIO
TABLE 69.NATERA INC.: NET SALES,
TABLE 70.NATERA INC.: KEY STRATERGIES
TABLE 71.PACGENOMICS: COMPANY SNAPSHOT
TABLE 72.PACGENOMICS: OPERATING SEGMENTS
TABLE 73.PACGENOMICS: PRODUCT PORTFOLIO
TABLE 74.PACGENOMICS: NET SALES,
TABLE 75.PACGENOMICS: KEY STRATERGIES
TABLE 76.PERKINELMER, INC.: COMPANY SNAPSHOT
TABLE 77.PERKINELMER, INC.: OPERATING SEGMENTS
TABLE 78.PERKINELMER, INC.: PRODUCT PORTFOLIO
TABLE 79.PERKINELMER, INC.: NET SALES,
TABLE 80.PERKINELMER, INC.: KEY STRATERGIES
TABLE 81.QUEST DIAGNOSTICS INC.: COMPANY SNAPSHOT
TABLE 82.QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS
TABLE 83.QUEST DIAGNOSTICS INC.: PRODUCT PORTFOLIO
TABLE 84.QUEST DIAGNOSTICS INC.: NET SALES,
TABLE 85.QUEST DIAGNOSTICS INC.: KEY STRATERGIES
TABLE 86.REPRODUCTIVE GENETIC INNOVATIONS (RGI): COMPANY SNAPSHOT
TABLE 87.REPRODUCTIVE GENETIC INNOVATIONS (RGI): OPERATING SEGMENTS
TABLE 88.REPRODUCTIVE GENETIC INNOVATIONS (RGI): PRODUCT PORTFOLIO
TABLE 89.REPRODUCTIVE GENETIC INNOVATIONS (RGI): NET SALES,
TABLE 90.REPRODUCTIVE GENETIC INNOVATIONS (RGI): KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SEGMENTATION
FIGURE 2.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030
FIGURE 3.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,BY TEST TYPE,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF CHROMOSOMAL ABNORMALITIES PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANEUPLOIDY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF X-LINKED DISEASES PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF SINGLE GENE DISORDERS PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HLA TYPING PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENDER SELECTION PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
FIGURE 19.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY REGION,2020
FIGURE 20.CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 21.JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 22.INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 23.SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 24.REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 25.LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 26.MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 27.AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 28.U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 29.CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 30.MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 31.GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 32.FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 33.U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 34.ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 35.REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40.COMPETITIVE DASHBOARD
FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 42.AGILENT TECHNOLOGIES, INC..: NET SALES ,($THOUSAND)
FIGURE 43.CEGAT GMBH.: NET SALES ,($THOUSAND)
FIGURE 44.ILLUMINA INC..: NET SALES ,($THOUSAND)
FIGURE 45.INVITAE CORPORATION.: NET SALES ,($THOUSAND)
FIGURE 46.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ,($THOUSAND)
FIGURE 47.NATERA INC..: NET SALES ,($THOUSAND)
FIGURE 48.PACGENOMICS.: NET SALES ,($THOUSAND)
FIGURE 49.PERKINELMER, INC..: NET SALES ,($THOUSAND)
FIGURE 50.QUEST DIAGNOSTICS INC..: NET SALES ,($THOUSAND)
FIGURE 51.REPRODUCTIVE GENETIC INNOVATIONS (RGI).: NET SALES ,($THOUSAND)